CPhI: Aesica to triple API sales in three years, to acquire assets in North America and India next year

Aesica Pharmaceuticals (Newcastle, UK), a provider of active pharmaceutical ingredients (APIs), formulations, and custom synthesis, says that it plans to triple annual revenues from the company’s API business by 2015. Aesica recorded total sales of about $250 million in 2011 and the company’s API business has annual sales of about $50 million. “We have a focused plan to increase the annual API revenues to at least $150 million by the end of 2015, and this will be through a mix of organic and inorganic growth,” Kevin Cook, managing...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers